{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:19:32Z","timestamp":1789402772828,"version":"build-2803163510"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.drup.2022.100822","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T04:46:54Z","timestamp":1646369214000},"page":"100822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma"],"prefix":"10.1016","volume":"61","author":[{"given":"Manfei","family":"Pi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2022.100822_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Trans. Med. Rev."},{"key":"10.1016\/j.drup.2022.100822_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2014.922180","article-title":"Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin","volume":"56","author":"Adekola","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drup.2022.100822_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/nu9101076","article-title":"Precision nutrition for targeting lipid metabolism in colorectal cancer","volume":"9","author":"Aguirre-Portol\u00e9s","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.drup.2022.100822_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fmolb.2020.00076","article-title":"Molecular mechanisms of adipogenesis: the anti-adipogenic role of AMP-activated protein kinase","volume":"7","author":"Ahmad","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.drup.2022.100822_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fphys.2012.00362","article-title":"Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling","volume":"3","author":"Alberghina","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.drup.2022.100822_bib6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metabol."},{"key":"10.1016\/j.drup.2022.100822_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100822_bib8","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1038\/sj.onc.1208555","article-title":"FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis","volume":"24","author":"Bandyopadhyay","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2022.100822_bib9","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1007\/s00018-020-03488-w","article-title":"Regulation of B-cell function by NF-kappaB c-Rel in health and disease","volume":"77","author":"Basavarajappa","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drup.2022.100822_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174158","article-title":"Tumor metabolism as a regulator of tumor-host interactions in the B-cell lymphoma microenvironment-fueling progression and novel brakes for therapy","volume":"20","author":"Beielstein","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2022.100822_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.49","article-title":"Lipid metabolic reprogramming in cancer cells","volume":"5","author":"Beloribi-Djefaflia","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drup.2022.100822_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science (New York, N. Y. )"},{"key":"10.1016\/j.drup.2022.100822_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tcb.2007.04.004","article-title":"p53: new roles in metabolism","volume":"17","author":"Bensaad","year":"2007","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.drup.2022.100822_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123553","article-title":"Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance","volume":"12","author":"Berendsen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100822_bib15","first-page":"311","article-title":"MicroRNAome genome: a treasure for cancer diagnosis and therapy","volume":"64","author":"Berindan-Neagoe","year":"2014","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.drup.2022.100822_bib16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41598-018-19182-8","article-title":"Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL","volume":"8","author":"Bhalla","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2022.100822_bib17","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1038\/s41598-020-78193-6","article-title":"SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma","volume":"10","author":"Bhalla","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2022.100822_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbcan.2018.05.002","article-title":"Targeting cancer\u2019s metabolic co-dependencies: A landscape shaped by genotype and tissue context","volume":"1870","author":"Bi","year":"2018","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.drup.2022.100822_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","article-title":"Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma","volume":"167","author":"Blachly","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drup.2022.100822_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drup.2022.100822_bib21","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17425255.2016.1239717","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses","volume":"12","author":"Bose","year":"2016","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.drup.2022.100822_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-77736-8_1","article-title":"Glucose metabolism in cancer","volume":"1063","author":"Bose","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.14274","article-title":"Leveraging insights into cancer metabolism-a symposium report","volume":"1462","author":"Cable","year":"2020","journal-title":"Anna. N. Y. Acad. Sci."},{"key":"10.1016\/j.drup.2022.100822_bib24","volume":"9","author":"Caiola","year":"2020","journal-title":"Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation"},{"key":"10.1016\/j.drup.2022.100822_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100671","article-title":"Towards the overcoming of anticancer drug resistance mediated by p53 mutations, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy","volume":"49","author":"Cao","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2022.100822_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijscr.2018.04.031","article-title":"Primary lymphoma of appendix presenting as acute appendicitis: A case report","volume":"48","author":"Caristo","year":"2018","journal-title":"Int. J. Surg. Case Rep."},{"key":"10.1016\/j.drup.2022.100822_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-5793(87)80292-2","article-title":"A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis","volume":"223","author":"Carling","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drup.2022.100822_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1046\/j.1365-2249.1999.01009.x","article-title":"Lymphocyte proliferation modulated by glutamine: involved in the endogenous redox reaction","volume":"117","author":"Chang","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.drup.2022.100822_bib29","first-page":"135","article-title":"CAR T cell therapy for B-cell lymphomas, Best practice & research","volume":"31","author":"Chavez","year":"2018","journal-title":"Clin. Haematol."},{"key":"10.1016\/j.drup.2022.100822_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092146","article-title":"Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma","volume":"13","author":"Choueiry","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100822_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao3810","article-title":"Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors","volume":"11","author":"Clement","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.drup.2022.100822_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060532","article-title":"HSP90 molecular chaperones, metabolic rewiring, and epigenetics: impact on tumor progression and perspective for anticancer therapy","volume":"8","author":"Condelli","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drup.2022.100822_bib33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1078-0432.CCR-17-2218","article-title":"Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K\u03b4 in Mature B-cell Malignancies","volume":"24","author":"Cooney","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2022.100822_bib34","doi-asserted-by":"crossref","first-page":"69219","DOI":"10.18632\/oncotarget.18215","article-title":"Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity","volume":"8","author":"Curtis","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100822_bib35","article-title":"New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy","volume":"51","author":"Dal","year":"2020","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Dalva-Aydemir","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2022.100822_bib37","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.4161\/cc.9.19.13302","article-title":"Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?","volume":"9","author":"Dang","year":"2010","journal-title":"Cell Cycle (Georgetown, Tex. )"},{"key":"10.1016\/j.drup.2022.100822_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drup.2022.100822_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc2274","article-title":"The interplay between MYC and HIF in cancer","volume":"8","author":"Dang","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2022.100822_bib40","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-09-0889","article-title":"MYC-induced cancer cell energy metabolism and therapeutic opportunities","volume":"15","author":"Dang","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2022.100822_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12308-012-0166-4","article-title":"FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma","volume":"6","author":"Danilova","year":"2013","journal-title":"J. Hematopathol."},{"key":"10.1016\/j.drup.2022.100822_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metabol."},{"key":"10.1016\/j.drup.2022.100822_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1515\/hmbci-2014-0045","article-title":"Adipose tissue dysfunction and its effects on tumor metabolism","volume":"21","author":"Diedrich","year":"2015","journal-title":"Hormone Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.drup.2022.100822_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2017.02.001","article-title":"Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges","volume":"30","author":"Diesendruck","year":"2017","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","article-title":"Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis","volume":"74","author":"Doherty","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100822_bib46","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1182\/blood-2005-12-4788","article-title":"Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth","volume":"107","author":"Doughty","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drup.2022.100822_bib47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/open.201900045","article-title":"Fluorescent Imaging for Cysteine Detection In Vivo with High Selectivity","volume":"8","author":"Duan","year":"2019","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.drup.2022.100822_bib48","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/0008-5472.CAN-13-0465","article-title":"Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors","volume":"73","author":"Dutta","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100822_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"D\u00fcvel","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2022.100822_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib51","first-page":"1","article-title":"Genetic alterations in B cell lymphoma subtypes as potential biomarkers for noninvasive diagnosis, prognosis, therapy, and disease monitoring","volume":"44","author":"Esmeray","year":"2020","journal-title":"Turkish J. Biol. = Turk biyoloji dergisi"},{"key":"10.1016\/j.drup.2022.100822_bib52","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.bcp.2006.08.009","article-title":"Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas","volume":"72","author":"Faber","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drup.2022.100822_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2006.04.023","article-title":"Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance","volume":"9","author":"Fantin","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100822_bib54","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"New England J. Med."},{"key":"10.1016\/j.drup.2022.100822_bib55","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-07-2489","article-title":"Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1","volume":"68","author":"Furuta","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100822_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","article-title":"Redundant angiogenic signaling and tumor drug resistance","volume":"36","author":"Gacche","year":"2018","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib57","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2147\/DDDT.S248872","article-title":"Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis","volume":"14","author":"Gao","year":"2020","journal-title":"Drug Design, Dev. Ther."},{"key":"10.1016\/j.drup.2022.100822_bib58","doi-asserted-by":"crossref","first-page":"14509","DOI":"10.1073\/pnas.1019386108","article-title":"PI3K\/Akt signaling requires spatial compartmentalization in plasma membrane microdomains","volume":"108","author":"Gao","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2022.100822_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100822_bib60","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1080\/10428194.2020.1742899","article-title":"Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma","volume":"61","author":"Gifford","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drup.2022.100822_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100797","article-title":"Impact of cancer metabolism on therapy resistance - Clinical implications","volume":"59","author":"Gon\u00e7alves","year":"2021","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib63","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.seminoncol.2017.10.002","article-title":"Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma","volume":"44","author":"Gooptu","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib64","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","article-title":"Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug","volume":"15","author":"Gout","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2022.100822_bib65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","article-title":"Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia","volume":"58","author":"Gregory","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.drup.2022.100822_bib66","first-page":"5","volume":"37","author":"Guan","year":"2019","journal-title":"Pharmacokinetics of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Mice: Potential Enterohepatic Circulation and Target-Mediated Disposition"},{"key":"10.1016\/j.drup.2022.100822_bib67","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100822_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103071","article-title":"Function and regulation of lipid signaling in lymphomagenesis: A novel target in cancer research and therapy","volume":"154","author":"Guo","year":"2020","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.drup.2022.100822_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161158","article-title":"IGF1R Derived PI3K\/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias","volume":"11","author":"Gusscott","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2022.100822_bib70","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","article-title":"Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors","volume":"9","author":"Hanker","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2022.100822_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drup.2019.04.001","article-title":"YY1 regulates cancer cell immune resistance by modulating PD-L1 expression","volume":"43","author":"Hays","year":"2019","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jbior.2017.06.003","article-title":"GSK3 and its interactions with the PI3K\/AKT\/mTOR signalling network","volume":"65","author":"Hermida","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.drup.2022.100822_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drup.2022.100822_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024703","article-title":"Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines","volume":"6","author":"Hussain","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2022.100822_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drup.2016.09.003","article-title":"The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target","volume":"29","author":"Icard","year":"2016","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-0-12-416618-9.00003-0","article-title":"Regulation of cancer metabolism by oncogenes and tumor suppressors","volume":"542","author":"Iurlaro","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.drup.2022.100822_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2018.11.003","article-title":"Cross-talk between signal transduction and metabolism in B cells","volume":"201","author":"Jellusova","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.drup.2022.100822_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","article-title":"Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects","volume":"32","author":"Jia","year":"2017","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib80","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1111\/cas.15055","article-title":"Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1\/CD20","volume":"112","author":"Jiang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2022.100822_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010125","article-title":"Amino acid transporters on the guard of cell genome and epigenome","volume":"13","author":"Kahya","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100822_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2018.09.001","article-title":"Precision medicine in head and neck cancer","volume":"40","author":"Kaidar-Person","year":"2018","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib83","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.redox.2017.04.018","article-title":"Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism","volume":"12","author":"Kalyanaraman","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.drup.2022.100822_bib84","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41467-018-03028-y","article-title":"Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL","volume":"9","author":"Kapadia","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2022.100822_bib85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41419-021-04353-9","article-title":"Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies","volume":"12","author":"Kapoor","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2022.100822_bib86","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2022.100822_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semcancer.2017.04.004","article-title":"Mitochondrial ribosomes in cancer","volume":"47","author":"Kim","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.drup.2022.100822_bib88","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3109\/10428194.2015.1113276","article-title":"CD79B limits response of diffuse large B cell lymphoma to ibrutinib","volume":"57","author":"Kim","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drup.2022.100822_bib89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-018-0056-9","article-title":"CXCR4 can induce PI3K\u03b4 inhibitor resistance in ABC DLBCL","volume":"8","author":"Kim","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2022.100822_bib90","doi-asserted-by":"crossref","first-page":"221","DOI":"10.15430\/JCP.2013.18.3.221","article-title":"Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells","volume":"18","author":"Kim","year":"2013","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.drup.2022.100822_bib91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-3-319-77736-8_7","article-title":"Non-Hodgkin Lymphoma Metabolism","volume":"1063","author":"Kirsch","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184417","article-title":"Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma","volume":"20","author":"Klener","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2022.100822_bib93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","article-title":"Immune checkpoint inhibitor combinations: Current efforts and important aspects for success","volume":"45","author":"Kon","year":"2019","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib95","first-page":"409","article-title":"The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid","volume":"64","author":"Korbecki","year":"2013","journal-title":"J. Physiol. Pharmacol.: Off. J. Pol. Physiol. Soc."},{"key":"10.1016\/j.drup.2022.100822_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/v11020119","article-title":"Chewing the Fat: The Conserved Ability of DNA Viruses to Hijack Cellular Lipid Metabolism","volume":"11","author":"Lange","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.drup.2022.100822_bib97","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nchembio.103","article-title":"Raft nanodomains contribute to Akt\/PKB plasma membrane recruitment and activation","volume":"4","author":"Lasserre","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metabol."},{"key":"10.1016\/j.drup.2022.100822_bib99","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/MCB.00165-09","article-title":"Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb","volume":"29","author":"Lee","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib100","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2022.100822_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100644","article-title":"Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer","volume":"46","author":"Leonetti","year":"2019","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib102","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41419-019-1626-x","article-title":"Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine","volume":"10","author":"Levin","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2022.100822_bib103","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12935-021-01746-w","article-title":"Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance","volume":"21","author":"Levin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2022.100822_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100720","article-title":"Surmounting cancer drug resistance: New insights from the perspective of N(6)-methyladenosine RNA modification","volume":"53","author":"Li","year":"2020","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib105","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1158\/1078-0432.CCR-12-3629","article-title":"Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2022.100822_bib106","doi-asserted-by":"crossref","first-page":"23157","DOI":"10.18632\/oncotarget.4319","article-title":"Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100822_bib107","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ccell.2019.05.002","article-title":"Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis","volume":"35","author":"Li","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2022.100822_bib108","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.drup.2022.100822_bib109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2016.02.001","article-title":"Could drugs inhibiting the mevalonate pathway also target cancer stem cells?","volume":"25","author":"Likus","year":"2016","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib110","article-title":"Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-\u03baB pathway","volume":"14","author":"Liu","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib111","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ncb3328","article-title":"LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress","volume":"18","author":"Liu","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.drup.2022.100822_bib112","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.celrep.2019.02.037","article-title":"p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake","volume":"26","author":"Lowman","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.drup.2022.100822_bib113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2015.08.006","article-title":"TP53 dysfunction in diffuse large B-cell lymphoma","volume":"97","author":"Lu","year":"2016","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.drup.2022.100822_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040576","article-title":"Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells","volume":"11","author":"Luanpitpong","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100822_bib115","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.drudis.2016.12.003","article-title":"Targeting amino acid metabolism for cancer therapy","volume":"22","author":"Lukey","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2022.100822_bib116","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.18632\/oncotarget.3006","article-title":"Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2","volume":"6","author":"Luo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100822_bib117","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metabol."},{"key":"10.1016\/j.drup.2022.100822_bib118","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00109-011-0735-5","article-title":"Metabolic regulation by p53","volume":"89","author":"Maddocks","year":"2011","journal-title":"J. Mol. Med. (Berlin, Germany)"},{"key":"10.1016\/j.drup.2022.100822_bib119","volume":"8","author":"Magaway","year":"2019","journal-title":"Targeting mTOR and Metabolism in Cancer: Lessons and Innovations"},{"key":"10.1016\/j.drup.2022.100822_bib120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13046-015-0147-4","article-title":"The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines","volume":"34","author":"Malm","year":"2015","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"key":"10.1016\/j.drup.2022.100822_bib121","doi-asserted-by":"crossref","first-page":"35349","DOI":"10.1038\/srep35349","article-title":"TRAF3 deficiency promotes metabolic reprogramming in B cells","volume":"6","author":"Mambetsariev","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2022.100822_bib122","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0960-9822(00)00742-9","article-title":"Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia","volume":"10","author":"Marsin","year":"2000","journal-title":"Curr. Biol.: CB"},{"key":"10.1016\/j.drup.2022.100822_bib123","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.bjc.6605007","article-title":"De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy","volume":"100","author":"Mashima","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2022.100822_bib124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2017.00549","article-title":"ASCT2 (SLC1A5)-Deficient Mice Have Normal B-Cell Development, Proliferation, and Antibody Production","volume":"8","author":"Masle-Farquhar","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2022.100822_bib125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1357-2725(01)00143-1","article-title":"Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation\/death","volume":"34","author":"Mat\u00e9s","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.drup.2022.100822_bib126","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.bbabio.2010.03.025","article-title":"The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies","volume":"1797","author":"Mathupala","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drup.2022.100822_bib127","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.18632\/oncotarget.6315","article-title":"Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K\/Akt\/ mTOR signaling","volume":"7","author":"Mediani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100822_bib128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.yexcr.2016.07.003","article-title":"Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma","volume":"346","author":"Miao","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.drup.2022.100822_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","article-title":"Exosomes and their role in tumorigenesis and anticancer drug resistance","volume":"45","author":"Milman","year":"2019","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fgene.2018.00427","article-title":"Metabolism and epigenetic interplay in cancer: regulation and putative therapeutic targets","volume":"9","author":"Miranda-Gon\u00e7alves","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.drup.2022.100822_bib131","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imr.12755","article-title":"Germinal center-derived lymphomas: The darkest side of humoral immunity","volume":"288","author":"Mlynarczyk","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.drup.2022.100822_bib132","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jbior.2014.10.003","article-title":"Lipid rafts as major platforms for signaling regulation in cancer","volume":"57","author":"Mollinedo","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.drup.2022.100822_bib133","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1194\/jlr.TR119000439","article-title":"Lipid rafts as signaling hubs in cancer cell survival\/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts","volume":"61","author":"Mollinedo","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.drup.2022.100822_bib134","doi-asserted-by":"crossref","first-page":"11355","DOI":"10.1096\/fj.202000705R","article-title":"Inhibitors of lipogenic enzymes as a potential therapy against cancer","volume":"34","author":"Montesdeoca","year":"2020","journal-title":"FASEB J.: Off. Publ. Feder. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib136","volume":"9","author":"Oh","year":"2020","journal-title":"Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics"},{"key":"10.1016\/j.drup.2022.100822_bib137","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000086984","article-title":"Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma","volume":"68","author":"Ohsawa","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.drup.2022.100822_bib138","volume":"21","author":"Pajak","year":"2019","journal-title":"2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents"},{"key":"10.1016\/j.drup.2022.100822_bib139","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3109\/10428194.2014.963575","article-title":"Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1\u03b1 and c-MYC","volume":"56","author":"Pang","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.drup.2022.100822_bib140","doi-asserted-by":"crossref","first-page":"86433","DOI":"10.18632\/oncotarget.13239","article-title":"Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100822_bib141","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-77736-8_3","article-title":"The Heterogeneity of Lipid Metabolism in Cancer","volume":"1063","author":"Park","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100779","article-title":"GSK3\u03b2 as a novel promising target to overcome chemoresistance in pancreatic cancer","volume":"58","author":"Pecoraro","year":"2021","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib143","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ebiom.2018.01.014","article-title":"Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway","volume":"28","author":"Pera","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drup.2022.100822_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100718","article-title":"Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies","volume":"53","author":"P\u00e9rez-Ruiz","year":"2020","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib145","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drup.2022.100822_bib146","first-page":"2465","volume":"19","author":"Rashmi","year":"2020","journal-title":"Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers"},{"key":"10.1016\/j.drup.2022.100822_bib147","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fonc.2018.00556","article-title":"Metabolic reprogramming of non-Hodgkin\u2019s B-cell lymphomas and potential therapeutic strategies","volume":"8","author":"Ricci","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib148","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/acs.molpharmaceut.7b00710","article-title":"Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin","volume":"14","author":"Rink","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drup.2022.100822_bib149","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"Rohwer","year":"2011","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib151","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2022.100822_bib152","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2022.100822_bib153","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/asheducation.V2012.1.402.3798516","article-title":"Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma","volume":"2012","author":"Sehn","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ Program"},{"key":"10.1016\/j.drup.2022.100822_bib154","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","article-title":"HIF-1: upstream and downstream of cancer metabolism","volume":"20","author":"Semenza","year":"2010","journal-title":"Curr Opin. Genet. Dev."},{"key":"10.1016\/j.drup.2022.100822_bib155","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib157","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1718","article-title":"Expression of hypoxia-inducible factor 1\u03b1, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors","volume":"10","author":"Shen","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.drup.2022.100822_bib158","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-020-00213-w","article-title":"Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma","volume":"8","author":"Singh","year":"2020","journal-title":"Cancer Metabol."},{"key":"10.1016\/j.drup.2022.100822_bib159","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2022.100822_bib160","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1158\/0008-5472.CAN-11-1715","article-title":"IKK\u03b2 and NF-\u03baB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1","volume":"71","author":"Sommermann","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2022.100822_bib161","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2022.100822_bib162","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.drup.2018.05.001","article-title":"How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance","volume":"38","author":"Stiewe","year":"2018","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib163","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3389\/fonc.2020.00792","article-title":"Metabolic reprogramming and epithelial-mesenchymal plasticity: opportunities and challenges for cancer therapy","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib164","doi-asserted-by":"crossref","first-page":"33085","DOI":"10.1074\/jbc.274.46.33085","article-title":"Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation","volume":"274","author":"Taha","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2022.100822_bib165","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cmet.2018.07.005","article-title":"A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3","volume":"28","author":"Tajan","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.drup.2022.100822_bib166","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI78239","article-title":"Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment","volume":"125","author":"Tanaka","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2022.100822_bib167","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fimmu.2019.00295","article-title":"Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease","volume":"10","author":"Tijaro-Ovalle","year":"2019","journal-title":"Front. Immunol"},{"key":"10.1016\/j.drup.2022.100822_bib168","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3960\/jslrt.56.89","article-title":"Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance","volume":"56","author":"Tomita","year":"2016","journal-title":"J. Clin. Exp. Hematopathol.: JCEH"},{"key":"10.1016\/j.drup.2022.100822_bib169","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/onc.2016.360","article-title":"Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction","volume":"36","author":"Tran","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2022.100822_bib170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcdb.2015.08.002","article-title":"Amino acid management in cancer","volume":"43","author":"Tsun","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib171","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/1535-7163.MCT-09-1061","article-title":"Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma","volume":"9","author":"Uddin","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2022.100822_bib172","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1074\/jbc.M511397200","article-title":"The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism","volume":"281","author":"Ullah","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2022.100822_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100806","article-title":"Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine","volume":"60","author":"Van den Bossche","year":"2022","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib174","article-title":"PI3K inhibitors are finally coming of age","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2022.100822_bib175","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.7150\/thno.36037","article-title":"CD36 tango in cancer: signaling pathways and functions","volume":"9","author":"Wang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2022.100822_bib176","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.drup.2022.100822_bib177","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib178","article-title":"Primary pulmonary diffuse large B-cell lymphoma with multiple ground-glass nodules as the primary manifestation: A case report","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.drup.2022.100822_bib179","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/his.13287","article-title":"MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma","volume":"71","author":"Wang","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.drup.2022.100822_bib180","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neo.2018.03.002","article-title":"Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma","volume":"20","author":"Wang","year":"2018","journal-title":"Neoplasia (New York, N. Y. )"},{"key":"10.1016\/j.drup.2022.100822_bib181","doi-asserted-by":"crossref","first-page":"8566","DOI":"10.1038\/srep08566","article-title":"Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2022.100822_bib182","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2022.100822_bib183","first-page":"312","volume":"35","author":"Wen","year":"2021","journal-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances"},{"key":"10.1016\/j.drup.2022.100822_bib184","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drup.2016.07.001","article-title":"Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics","volume":"28","author":"Wijdeven","year":"2016","journal-title":"Drug Resist. Updat.: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"10.1016\/j.drup.2022.100822_bib185","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1158\/0008-5472.CAN-13-0382-T","article-title":"An essential requirement for the SCAP\/SREBP signaling axis to protect cancer cells from lipotoxicity","volume":"73","author":"Williams","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100822_bib186","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.drup.2022.100822_bib187","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: a new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.drup.2022.100822_bib188","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.molcel.2013.01.035","article-title":"AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1","volume":"49","author":"Wu","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2022.100822_bib189","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fonc.2018.00632","article-title":"Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion","volume":"8","author":"Xia","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib190","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.61","article-title":"MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma","volume":"7","author":"Xiong","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drup.2022.100822_bib191","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","article-title":"Ferroptosis: mechanisms and links with diseases","volume":"6","author":"Yan","year":"2021","journal-title":"Signal Trans. Targeted Ther."},{"key":"10.1016\/j.drup.2022.100822_bib192","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.18632\/oncotarget.24684","article-title":"Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer","volume":"10","author":"Yang","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100822_bib193","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: a hallmark of cancer metabolism","volume":"19","author":"Yang","year":"2017","journal-title":"Ann. Rev. Biomed. Eng."},{"key":"10.1016\/j.drup.2022.100822_bib194","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coph.2015.05.016","article-title":"Drugging PI3K in cancer: refining targets and therapeutic strategies","volume":"23","author":"Yap","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drup.2022.100822_bib195","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160479","article-title":"mTOR complex 1 signalling regulates the balance between lipid synthesis and oxidation in hypoxia lymphocytes","volume":"37","author":"Yin","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.drup.2022.100822_bib196","first-page":"527","article-title":"Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma","volume":"22","author":"Yin","year":"2017","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"10.1016\/j.drup.2022.100822_bib197","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010140","article-title":"Amino acid metabolism in cancer drug resistance","volume":"11","author":"Yoo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2022.100822_bib198","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.blre.2016.10.001","article-title":"NF-\u03baB signaling pathway and its potential as a target for therapy in lymphoid neoplasms","volume":"31","author":"Yu","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.drup.2022.100822_bib199","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12935-020-01614-z","article-title":"Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies","volume":"20","author":"Yue","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2022.100822_bib200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib201","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","article-title":"Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.drup.2022.100822_bib202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2022.100822_bib203","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.humpath.2014.06.032","article-title":"Clinicopathological implications of nuclear factor \u03baB signal pathway activation in diffuse large B-cell lymphoma","volume":"46","author":"Zhao","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.drup.2022.100822_bib204","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.60","article-title":"Targeting cellular metabolism to improve cancer therapeutics","volume":"4","author":"Zhao","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2022.100822_bib205","first-page":"1528","article-title":"Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma","volume":"52","author":"Zhong","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.drup.2022.100822_bib206","first-page":"45","article-title":"Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins","volume":"23","author":"Zhuang","year":"2010","journal-title":"Modern Pathol. Off. J. U. S. Canad. Acad. Pathol., Inc"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764622000218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764622000218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:57:53Z","timestamp":1761281873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764622000218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":206,"alternative-id":["S1368764622000218"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2022.100822","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2022.100822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100822"}}